Takashima Rie, Takasawa Hironao, Kawasako Kazufumi, Ohyama Wakako, Okada Emiko, Narumi Kazunori, Fujiishi Yohei, Wako Yumi, Yasunaga Katsuaki, Hattori Akiko, Kawabata Masayoshi, Nakadate Kiyoko, Nakagawa Munehiro, Hamada Shuichi
LSI Medience Corporation, 14-1 Sunayama, Kamisu-shi, Ibaraki 314-0255, Japan.
LSI Medience Corporation, 14-1 Sunayama, Kamisu-shi, Ibaraki 314-0255, Japan.
Mutat Res Genet Toxicol Environ Mutagen. 2015 Mar;780-781:18-24. doi: 10.1016/j.mrgentox.2014.10.007. Epub 2014 Oct 30.
As part of a collaborative study by the Collaborative Study Group for Micronucleus Test (CSGMT) of the Mammalian Mutagenicity Study Group (MMS) in the Japanese Environmental Mutagen Society (JEMS), the present study evaluated the effectiveness of the repeated dose liver micronucleus (RDLMN) assay. Two genotoxic hepatocarcinogens, dimethylnitrosamine (DMN) and 2-acetylaminofluorene (2-AAF), were administered orally to male rats (6 weeks old at the initial dosing) once daily for 14 and 28 days to evaluate the micronucleus (MN) inducibility in the liver. In addition, these chemicals were evaluated for MN inducibility in the bone marrow (BM) and gastrointestinal (GI) tract, i.e. glandular stomach and colon of the same animals used in the RDLMN assay. As a result, both chemicals produced positive results in the liver, although a weak positive response was given by 2-AAF. DMN gave negative results in the tissues other than the liver. 2-AAF produced positive responses in the BM and glandular stomach, and a prominent response was particularly observed in the glandular stomach, which is directly exposed to the test chemicals by gavage. The present results suggest that the RDLMN assay is a useful method for detecting genotoxic hepatocarcinogens, and that it is especially effective for evaluating test chemicals, such as DMN, undetectable by the BM and GI tract MN assay. Moreover, the results in this investigation indicate that the use of multiple tissues in the study integrating the MN tests is more effective than using a single tissue, for detection of the MN induction produced by chemical exposure to rats, and helps to determine the characteristics of the test chemicals.
作为日本环境诱变剂学会(JEMS)哺乳动物诱变性研究组(MMS)微核试验协作研究组(CSGMT)合作研究的一部分,本研究评估了重复剂量肝脏微核(RDLMN)试验的有效性。给雄性大鼠(初次给药时6周龄)口服两种遗传毒性肝癌致癌物,二甲基亚硝胺(DMN)和2-乙酰氨基芴(2-AAF),每天一次,持续14天和28天,以评估肝脏中的微核(MN)诱导能力。此外,还评估了这些化学物质在骨髓(BM)和胃肠道(GI),即RDLMN试验中所用相同动物的腺胃和结肠中的MN诱导能力。结果,两种化学物质在肝脏中均产生阳性结果,尽管2-AAF给出的是弱阳性反应。DMN在肝脏以外的组织中给出阴性结果。2-AAF在骨髓和腺胃中产生阳性反应,在腺胃中尤其观察到显著反应,腺胃通过灌胃直接接触受试化学物质。目前的结果表明,RDLMN试验是检测遗传毒性肝癌致癌物的一种有用方法,对于评估骨髓和胃肠道MN试验无法检测到的受试化学物质,如DMN,尤其有效。此外,本研究结果表明,在整合MN试验的研究中使用多个组织比使用单个组织更有效,用于检测化学物质暴露于大鼠后产生的MN诱导,并有助于确定受试化学物质的特性。